Načítá se...
Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
AIMS: Sodium‐glucose co‐transporter type 2 (SGLT2) inhibitors are a new class of anti‐hyperglycaemic agents in type 2 diabetes mellitus (T2DM). This review examines their mechanism of action and provides an overview of safety and efficacy from the main studies of SGLT2 inhibitors marketed in the Uni...
Uloženo v:
| Vydáno v: | Int J Clin Pract |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5518299/ https://ncbi.nlm.nih.gov/pubmed/28440009 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12937 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|